Letrozol Amarox

Letrozole, the active ingredient in Letrozol Amarox, is an aromatase inhibitor presented as an oral tablet for systemic administration. It works by lowering estrogen levels and is used primarily to treat hormone receptor‑positive breast cancer in postmenopausal women, both in the adjuvant and metastatic settings, and may be prescribed as part of a comprehensive endocrine therapy regimen.

GNH USA supplies Letrozol Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and individual orders.

Letrozole is employed in the management of estrogen‑dependent breast cancer, targeting hormone‑driven disease pathways.

Hormone receptor‑positive breast cancer (adjuvant): reduces risk of disease recurrence after surgery in postmenopausal women. Metastatic hormone receptor‑positive breast cancer: slows tumor progression and extends survival in postmenopausal patients with advanced disease. Neoadjuvant therapy for estrogen‑responsive tumors: decreases tumor size before surgery, facilitating breast‑conserving procedures.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea

Serious or Rare Side Effects: - Osteoporosis or bone fractures - Severe liver injury - Pulmonary embolism or deep‑vein thrombosis

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate history of heart disease before initiating therapy. - Bone health monitoring: perform baseline bone mineral density testing and consider calcium/vitamin D supplementation. - Liver function evaluation: check hepatic enzymes prior to treatment and periodically during therapy. - Drug interactions: review concomitant medications that may affect estrogen metabolism. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Letrozole can interact with other medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Tamoxifen: combined use may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may increase plasma levels modestly. - Warfarin: may enhance anticoagulant effect; monitor INR. - Antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours.